Advertisement

Search Results

Advertisement



Your search for ,maY matches 17165 pages

Showing 16851 - 16900


prostate cancer

Increased Radiation Dose With Hypofractionated vs Conventional Radiation Therapy Does Not Improve Biochemical/Clinical Failure Rate in Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Alan Pollack, MD, PhD, of University of Miami Miller School of Medicine, and colleagues compared escalated radiation dose using hypofractionated vs conventional fractionation intensity-modulated radiation therapy in men with favorable-...

bladder cancer
issues in oncology

STAG2 Mutation Found Linked to Low-Risk Bladder Cancer

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer. The findings, published in Nature Genetics, identified STAG2 as one of the most commonly mutated genes in bladder cancer,...

gastroesophageal cancer
issues in oncology

Researchers Identify Four Genetic Variants Linked to Esophageal Cancer and Barrett’s Esophagus

An international consortium co-led by researchers at Fred Hutchinson Cancer Research Center and the QIMR Berghofer Medical Research Institute in Australia has identified four genetic variants associated with an increased risk of esophageal cancer and its precursor, Barrett’s esophagus. The...

survivorship

Improvements Needed in Use of Survivorship Care Plans

Survivorship care plans, consisting of treatment summaries and follow-up plans, are intended to promote coordination of post-treatment cancer care, but little is known about how they are being used in routine oncology practice. In a study reported in the Journal of the National Cancer...

head and neck cancer

Increased Risk of Long-Term Cardiovascular Mortality and All-Cause Mortality in Patients With Differentiated Thyroid Carcinoma

In a study reported in the Journal of Clinical Oncology, Esther N. Klein Hesselink, of University Medical Center Groningen in the Netherlands, and colleagues evaluated long-term cardiovascular mortality in patients with differentiated thyroid cancer. They found that risk of cardiovascular and...

lung cancer
issues in oncology

Simple Blood Test May Diagnose Lung and Other Cancers

A simple blood test that measures serum free fatty acids and their metabolites may detect early-stage lung cancer and its recurrence, according to a study from The Cleveland Clinic presented at the ANESTHESIOLOGY™ 2013 Annual Meeting in San Francisco (Abstract A4267). The study was presented ...

solid tumors
bladder cancer

Standard and Reduced High-Dose Volume Radiation Therapy for Muscle-Invasive Bladder Cancer Have Comparable Tumor Control

Standard and reduced high-dose volume radiation therapy for muscle-invasive bladder cancer provide comparable tumor control and decreased late toxicity when compared to surgery, according to a study published in the October issue of the International Journal of Radiation Oncology...

prostate cancer
issues in oncology

LAT Inhibition May Be a New Therapeutic Option for Metastatic Castration-Resistant Prostate Cancer

L-type amino acid transporters (LAT) uptake neutral amino acids including L-leucine into cells, stimulating mTOR complex 1 (mTORC1) signaling and protein synthesis. LAT1 and LAT3 are overexpressed at different stages of prostate cancer and are involved in increasing nutrients and stimulating cell...

prostate cancer
supportive care

No Additional Benefit of Venlafaxine or Soy Protein vs Placebo on Hot Flashes in Men With Prostate Cancer

Hot flashes occur in approximately 80% of androgen-deprived men. In a randomized study reported in the Journal of Clinical Oncology by Mara Z. Vitolins, DrPH, MPH, RD, of Wake Forest School of Medicine, and colleagues, neither venlafaxine nor soy protein—both of which have been used to...

breast cancer

Women With Lower Pretreatment Estrogen Levels at Greater Risk of Breast Cancer During Estrogen-Plus-Progestin Therapy

In a study reported in the Journal of the National Cancer Institute, Ghada N. Farhat, PhD, of University of Balamand in Beirut, and colleagues found that women with lower pretreatment endogenous estrogen levels are at greatest risk of breast cancer during estrogen-plus-progestin therapy. Study...

issues in oncology
breast cancer

PAM50 Risk of Recurrence Score Provides Strongest Prognostic Information for Risk Beyond 5 Years in Estrogen Receptor–Positive Breast Cancer

Adjuvant endocrine therapy beyond 5 years reduces recurrence in patients with estrogen receptor–positive breast cancer. Recent studies from the transATAC cohort have shown that immunohistochemical markers (IHC4), Oncotype DX recurrence score, and PAM50 risk of recurrence score are associated...

breast cancer

Program Chairs Highlight Abstracts of Interest for the 2013 CTRC-AACR San Antonio Breast Cancer Symposium

The Program Chairs of the 2013 CTRC-AACR San Antonio Breast Cancer Symposium, which will be held December 10–14, 2013, have highlighted what they consider to be the most important abstracts to be presented at the Symposium. In a telebriefing in advance of the December meeting, C. Kent...

issues in oncology

Substantial Proportion of Older Patients Receiving First-Line Chemotherapy Experience Functional Decline

In a study reported in Journal of Clinical Oncology, Stéphanie Hoppe, PhD, of Institut Bergonié in Bordeaux, France, and colleagues assessed functional status in older patients with cancer receiving first-line chemotherapy using the Activities of Daily Living (ADL) scale. Clinically...

colorectal cancer
issues in oncology

PIK3CA Mutation Predictive of Relapse-Free Survival Benefit of Aspirin in Colorectal Cancer

Although nonsteroidal anti-inflammatory drugs such as aspirin have been shown to be protective against colorectal cancer and are associated with reduced disease recurrence and improved outcome, they are also associated with toxicities that limit their use in therapy. Recent data suggest that the...

breast cancer

ASCO and the College of American Pathologists Issue Updated Guideline on HER2 Testing in Breast Cancer

ASCO and the College of American Pathologists (CAP) today issued a joint, updated guideline to improve the accuracy and reporting of human epidermal growth factor receptor 2 (HER2) testing in patients with invasive breast cancer. The six-recommendation guideline is based on a systematic review of...

health-care policy
survivorship

Older Cancer Survivors in Rural Areas Forgo Health Care Due to Cost

Rural cancer survivors aged 65 or older were 66% more likely to forgo routine follow-up health care and 54% more likely to forgo dental care because of cost, compared with their urban counterparts, according to a study by Nynikka Palmer, DrPH, MPH, Post-doctoral Fellow in the Department of Social...

breast cancer

Lactation May Be Linked to Triple-Negative Breast Cancer in Mexican Women

Scientific data suggest that a woman reduces her risk of breast cancer by breastfeeding, having multiple children, and giving birth at a younger age. However, a study led by the University of California, San Diego School of Medicine, indicates that women of Mexican descent may not fit that profile. ...

lymphoma

Genetic Anti-Inflammatory Defect May Predispose Children to Lymphoma

New research shows that children with an inherited genetic defect in a critical anti-inflammatory pathway have a genetic predisposition to lymphoma. Results of the study, published online today in Blood, reveal an important association between the genetic defect, which causes chronic intestinal...

breast cancer

Breast Cancer Rates Are Rising Among African American Women

Although, historically, white women aged 40 years and older have had the highest incidence rates of breast cancer, the rising rate of breast cancer among African American women—especially among women aged 50 to 59—is narrowing the gap, according to a study by American Cancer Society...

prostate cancer
issues in oncology

ECC 2013: French Study Finds Routine PSA Screening Does More Harm Than Good

There is no consensus on the value of routine prostate-specific antigen (PSA) screening. Weighing in on this issue, investigators presented a study at the European Cancer Congress 2013 in Amsterdam (Abstract 1481) suggesting that population-based PSA screening does more harm than good. The...

Treatment With Losartan May Improve Delivery of Chemotherapy Drugs in Tumors

Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In a report published in Nature Communications, investigators from Massachusetts General Hospital (MGH) described how the angiotensin...

breast cancer

ECC 2013: Strong Showing for Ado-Trastuzumab Emtansine in Heavily Pretreated Advanced HER2-Positive Breast Cancer

Results of the phase III TH3RESA trial show that the antibody-conjugate ado-trastuzumab (Kadcyla, previously known as T-DM1) extends progression-free survival in women with advanced HER2-positive breast cancer that progressed on two or more previous HER2-directed therapies including trastuzumab...

lung cancer

ECC 2013: Novel Anti-PD-L1 Antibody Achieves Durable Responses in Phase I Study of Patients With Metastatic NSCLC, Smokers Included

For the first time, an immunotherapy shows promise in smokers with non–small cell lung cancer (NSCLC). The engineered monoclonal antibody MPDL3280A achieved encouraging and durable responses in a phase I study in metastatic NSCLC in smokers and nonsmokers, and with squamous and adenocarcinoma ...

prostate cancer
survivorship

Men With Advanced Prostate Cancer Worry More About Burdening Family and Friends Than Dying, Survey Finds

Men with advanced prostate cancer are now living longer than ever, and it is estimated that one in six U.S. men will be diagnosed with prostate cancer in their lifetime. However, little research has been conducted to understand the psychosocial needs of these men and their caregivers after...

breast cancer
gynecologic cancers
issues in oncology

ECC 2013: Continuous Combined Hormone Replacement Therapy Protects Against Endometrial Cancer

According to an analysis of the Women’s Health Initiative, continuous combined use of estrogen plus progestin reduces the risk of endometrial cancer among postmenopausal women. The study was reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA13) by Rowan Chlebowski, MD,...

breast cancer

FDA Approves Neoadjuvant Pertuzumab for Early-Stage Breast Cancer

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and docetaxel for patients with early-stage breast cancer in the neoadjuvant setting. Pertuzumab is the first FDA-approved drug for the neoadjuvant...

prostate cancer

Telomere Length May Be a Prognostic Marker for Prostate Cancer

Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...

lung cancer

Repurposed Antidepressants May Have Potential to Treat Small Cell Lung Cancer

A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small cell lung cancer, according to a study published in Cancer Discovery. Based on data generated using bioinformatics, two drugs approved by the U.S. Food and ...

ASTRO: Protecting Hippocampus During Whole-Brain Radiation Substantially Reduces Rate of Memory Loss in Cancer Patients

Protecting the stem cells that reside in and around the hippocampus substantially reduces the rate of cancer patients' memory loss during whole-brain radiotherapy without a significant risk of recurrence in that area of the brain, a new study shows. Results of the phase II clinical trial of...

head and neck cancer

ASTRO: Intensity Modulated Proton Therapy May Preserve Quality of Life in Patients With Oropharyngeal Cancer

A new study from researchers at The University of Texas MD Anderson Proton Therapy Center found that the use of feeding tubes in patients with oropharyngeal cancer treated with intensity modulated proton therapy decreased by more than 50% compared to patients treated with intensity modulated...

Large Retrospective Study Finds Association Between Marriage and Cancer Outcomes

New results from a large retrospective study of the National Cancer Institute’s SEER database, published in the Journal of Clinical Oncology, show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients. Researchers also found...

prostate cancer
supportive care

Abiraterone Acetate/Prednisone Combination Delays Decline in Quality of Life in Men With Metastatic Prostate Cancer

According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...

lymphoma

Phase II Study Shows Activity of Selective Aurora A Kinase Inhibitor Alisertib in Relapsed/Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphoma

Aurora A kinase is overexpressed in aggressive lymphomas and may correlate with more histologically aggressive forms of disease. In a phase II study reported in Journal of Clinical Oncology, Jonathan W. Friedberg, MD, of University of Rochester Wilmot Cancer Center, and colleagues assessed the...

cns cancers

ASTRO: Younger Adults With a Limited Number of Brain Metastases Have Improved Overall Survival After Stereotactic Radiosurgery Alone

When treated with stereotactic radiosurgery that is not combined with whole-brain radiotherapy, adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented on Sunday, September 22, at the American Society for Radiation...

cns cancers

ASTRO: Proton Therapy Yields Encouraging Outcomes for Pediatric Brain Tumor Patients

When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented on Sunday, September 22, at the American Society for Radiation Oncology’s 55th Annual Meeting...

survivorship

Childhood Cancer Survivors Who Received Nephrotoxic Therapy May Be at Greater Risk for Late Renal Problems

A large study assessing glomerular function in adult survivors of childhood cancers who were treated with certain chemotherapy drugs or kidney surgery found that they had worse kidney function, which did not recover over time, compared with adult survivors who were not given nephrotoxic therapy....

breast cancer

Mindfulness-Based Stress Reduction Superior to Supportive-Expressive Therapy for Distressed Survivors of Breast Cancer

Mindfulness-based cancer recovery was shown in to be superior to supportive-expressive group therapy decreasing symptoms of stress and improving overall quality of life and social support among survivors of stage I to III breast cancer who were distressed, according to a study reported in Journal...

multiple myeloma

Researchers Uncover Root Cause of Multiple Myeloma Relapse

Researchers have discovered why multiple myeloma frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. The study, published in Cancer Cell, was a collaboration between researchers at Princess Margaret Hospital in Toronto, Mayo Clinic in...

colorectal cancer

Deficient DNA Mismatch Repair Associated With Favorable Prognosis in Proximal Tumors in Stage III Colon Cancer Patients Receiving Adjuvant FOLFOX

In an analysis reported in Journal of Clinical Oncology, Frank A. Sinicrope, MD, of the Mayo Clinic and North Central Cancer Treatment Group (NCCTG), and colleagues investigated the association of deficient DNA mismatch repair with prognosis in patients with stage III colon cancer treated with...

colorectal cancer

Presence of RAS Mutations in Metastatic Colorectal Cancer Predictive of Negative Response to Panitumumab/FOLFOX4 Treatment

Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-EGFR therapy. However, other activating RAS mutations may predict poorer outcome with anti-EGFR therapy. In an analysis reported in The New England Journal of Medicine by Jean-Yves Douillard,...

lung cancer
issues in oncology

MicroRNA Molecule Found to Be a Potent Tumor Suppressor in Lung Cancer

New research shows that microRNA-486 (miR-486) is a potent tumor-suppressor molecule in lung cancer, and that it helps regulate the proliferation and migration of lung cancer cells, as well as the induction of apoptosis in those cells. Published in the Proceedings of the National Academy of...

breast cancer

Young Breast Cancer Patients May Overestimate Benefit of Contralateral Prophylactic Mastectomy

Young women with breast cancer may overestimate the risk that cancer will occur in their other healthy breast and decide to undergo contralateral prophylactic mastectomy, a survey conducted by Dana-Farber Cancer Institute investigators indicated. The survey also shows that many patients may opt for ...

skin cancer

PDK1 Gene Identified as New Target for Melanoma Treatment

According to new research at Sanford-Burnham Medical Research Institute a gene encoding the enzyme phosphoinositide-dependent kinase-1 (PDK1) plays an essential role in the development and progression of melanoma. The finding, published online in Oncogene, may offer insight toward a new approach to ...

New Medical Device Treats Urinary Symptoms Related to Benign Prostatic Hyperplasia

The U.S. Food and Drug Administration has authorized the marketing of the UroLift system, a permanent implant to relieve low or blocked urine flow in men age 50 and older with benign prostatic hyperplasia. As men age, the prostate can become enlarged, also known as benign prostatic hyperplasia....

leukemia

FDA Grants Volasertib Breakthrough Therapy Designation in Acute Myeloid Leukemia

Boehringer Ingelheim Pharmaceuticals, Inc, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase (Plk), which being evaluated for the treatment of patients aged 65 or older with...

breast cancer

Exploratory Analysis Suggests Response-Guided Neoadjuvant Therapy for Breast Cancer May Improve Survival

In an exploratory analysis of long-term survival data from the GeparTrio trial reported in Journal of Clinical Oncology, Gunter von Minckwitz, MD, of the German Breast Group in Neu-Isenburg, and colleagues found that response-guided neoadjuvant chemotherapy appears to improve disease-free survival...

lung cancer

New Plasma Biomarker Identified for the Diagnosis of Lung Cancer

A new plasma biomarker, isocitrate dehydrogenase 1 (IDH1), has been shown to be more sensitive in detecting non–small cell lung cancer (NSCLC) than currently used biomarkers, including CEA, Cyfra21-1, and CA125, according to a study published in Clinical Cancer Research. The study by Jie He,...

breast cancer

Gene Expression–Based Biomarker Predicts Long-Term Risk of Breast Cancer Recurrence

A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor–positive breast cancer found that only the breast cancer index (BCI)—a biomarker based on the expression levels of seven tumor-specific genes—accurately identified patients...

breast cancer

ODAC Recommends Accelerated Approval of Pertuzumab for HER2-Positive, Early-Stage Breast Cancer

The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 0, with one abstention, in favor of recommending accelerated approval of a pertuzumab (Perjeta) regimen for neoadjuvant treatment in patients with high-risk, HER2-positive, early-stage breast...

prostate cancer

Ipilimumab Fails to Significantly Prolong Survival in Patients With Advanced Prostate Cancer

Bristol-Myers Squibb Company, the manufacturer of ipilimumab (Yervoy), released results from its phase III randomized double-blind study investigating the drug in men with metastatic castration-resistant prostate cancer. The study findings show that ipilimumab, a monoclonal antibody that blocks the ...

Advertisement

Advertisement




Advertisement